Our Partner Wins Participation in EURO 2.8 Million Program to Develop its Nanocarrier Treatment for Infectious Diseases

 

THE CLR-TARGOSPHERE NANOCARRIER CONTAINING CURCUMIN

Rodos Biotarget GmbH, developer of the C-Lectin Receptor TargoSphere which is licensed to us to treat oncologic and neurodegenerative diseases, has been awarded participation in a EUR 2.8 million research consortium by Germany’s Foreign Ministry of Education and Research in order to develop a nanocarrier-targeted drug approach for treatment-resistant tuberculosis.

In recent years, antibiotic resistance of bacterial pathogens has reached a threatening dimension on the global scale. To meet this challenge, the German Federal Ministry of Education and Research (BMBF) initiated a program "Promoting Diagnostics and Novel Therapies for the Treatment of Bacterial Infections".

Embedded in the German Government’s High-Tech Strategy and its Framework Program Health Research, this program intends to enable new therapeutic developments into innovative products, and pave their way towards clinical applications.

In the framework of a consortium of high-profile German research facilities, our collaborating partner, Rodos Biotarget GmbH will advance their proprietary targeted nanomedical therapeutic approach to pulmonary tuberculosis. To be developed as an inhalation therapy, this treatment will directly target infected pulmonary cells to address TB pathogens.

For future developments, the underlying principle for employing this proprietary nanocarrier to treat pulmonary cellular infections and to reach impaired lung cells will also be developed for treatments of other pulmonary diseases.

About Rodos Biotarget GmbH

Rodos Biotarget has developed a platform technology called the TargoSphere® for nanocarrier-enabled targeted and efficient drug delivery. This technology is suitable for prophylactic and therapeutic applications in multiple disease areas of high medical need.

These include cancers, which we at Augustus BioTarget are studying, such as colon cancer, and neurological disorders such as Chronic Traumatic Encephalopathy (CTE), Alzheimer's Disease, Parkinson Disease, and Multiple Sclerosis.

In order to commercialize its patented technology platform, Rodos Biotarget primarily relies on collaborations with major pharmaceutical companies. In addition, the company promotes in-house therapy developments including TargoBioticsTM for the treatment of intracellular bacterial infections, TargoVirTM for the treatment of chronic viral diseases, and other nanomedicines for the treatment of type 2 diabetes as well as liver diseases such as acute liver failure, liver fibrosis, urea cycle deficiencies and liver cancer.

For more information, please visit: biotargeting.eu